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Introduction
Signiﬁ cant progress in organ transplantation in the past 
two decades has been mostly driven by improvement of 
short-term graft and patient survival due, in particular, to 
the use of calcineurin inhibitors (CNIs), which have 
reduced the rate of acute rejection considerably [1]. 
Nevertheless, this improvement in graft survival in the 
ﬁ rst year after transplantation has had a limited impact 
on long-term outcomes, which has only slowly improved 
[2]. Th is limited impact can be explained in part by the 
serious chronic adverse events associated with the use of 
CNIs, such as the increased risk of malignancies and 
cardiovascular events, which are the most frequent 
causes of death in kidney transplant patients. Import-
antly, CNIs also contribute to the development of chronic 
graft injuries [3]. Data suggest that CNI-sparing regimens 
could improve long-term graft and patient survival, as 
shown by Gallagher and colleagues, who reported 
improved 20-year graft survival in patients in whom 
cyclosporine (CsA) had been converted to azathioprine 
3  months after trans plantation in comparison with 
patients who continued CsA [4].
Th e advent of new immunosuppressive agents, such as 
mTOR inhibitors, has allowed CNI-based regimens to be 
used sparingly, and tests the hypothesis that CNIs con-
tribute to chronic allograft nephropathy [5,6]. Sirolimus 
(SRL) binds to the mTOR complex and inhibits immune 
cell proliferation and diﬀ erentiation. A pioneering trial of 
CNI withdrawal from SRL-based therapy demonstrated 
improved 4-year graft survival with improved renal 
function [7], showing that maintenance therapy with SRL 
and mycophenolate mofetil (MMF) was eﬀ ective, thus 
paving the way to conversion strategies.
Late conversion
In the CONVERT study, 830 patients were randomised 6 
to 120 months after transplantation (mean 3.1 years) with 
a 2:1 ratio to either convert to SRL or to continue on a 
CNI (cyclosporine or tacrolimus) [8]. In addition, 
patients received steroids and adapted doses of either 
MMF or azathioprine. Th e primary endpoints were renal 
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function, evaluated by the Nankivell glomerular ﬁ ltration 
rate (GFR), and the cumulative rates of biopsy-proved 
acute rejection (BPAR), graft loss, or death at 12 months. 
Patients were stratiﬁ ed by baseline GFR: either 20 to 
40 ml/minute or >40 ml/minute. Intent-to-treat analyses 
at 12 and 24  months showed no signiﬁ cant treatment 
diﬀ erences in GFR. Th e mean GFR at 12 and 24 months 
was signiﬁ cantly higher in the group converted to SRL in 
comparison with the CNI group for patients with base-
line GFR >40  ml/minute who remained on assigned 
therapy (63.6 vs. 61.1 ml/minute, P = 0.006 and 62.6 vs. 
59.9 ml/minute, P = 0.009, at 12 and 24 months respect-
ively) and for the subgroup with baseline GFR >40  ml/
minute and a urinary protein-to-creatinine ratio ≤0.11 
(66.2 vs. 60.1 ml/minute, P = 0.004 and 63.8 vs. 59.0 ml/
minute, P  =  0.049, at 12 and 24  months respectively). 
Graft and patient survival and the incidence of BPAR 
were similar in both groups. Th e discontinuation rate was 
higher in the SRL group at 12  months (15.7 vs. 9.5%, 
P = 0.013) but not at 24 months (25.8 vs. 20.0%, P = 0.07), 
with more adverse events during the ﬁ rst 6 months after 
randomisation. Interestingly, the incidence of malig-
nancies was reduced after SRL conversion (3.8 vs. 11% at 
24 months, P <0.001) [9].
A study of late conversion was performed with evero-
limus (EVL) [10]. In the ASCERTAIN study, 398 patients 
were randomised (mean 5.6  years after transplantation) 
to continue CNIs (cyclosporine or tacrolimus), to 
minimise CNI therapy with the addition of EVL or to 
convert to EVL. Th e mean measured GFR at 24 months, 
the primary endpoint, was not signiﬁ cantly diﬀ erent 
between the three groups, while proteinuria was 
signiﬁ cantly higher in the EVL group at 12  months. A 
post-hoc analysis in patients with better baseline graft 
function (deﬁ ned by Nankivell GFR >50 ml/minute) and 
who remained on the randomised treatment regimen has 
shown that the increase in GFR from baseline to 
month 24 was signiﬁ cantly greater in the CNI elimination 
group than in control patients. Adverse events resulted in 
discontinuation for 28.3% of patients (P <0.001 vs. CNI-
free patients) in the CNI elimination group, for 16.7% of 
patients in the CNI minimisation group (P  =  0.02 vs. 
CNI-free patients) and for only 4% of patients who 
continued on a CNI-based regimen. Th e incidence of 
malignancies was not diﬀ erent between the three groups 
(7.1%, 7.6% and 5.7%, respectively).
Th ese data suggest that the renal beneﬁ t of a late 
conversion, 1 year or more after transplantation, is 
limited, except in patients with good renal function and 
without proteinuria. Renal biopsy prior to conversion is 
useful to select patients without mild to severe chronic 
renal allograft damage in whom conversion from CNIs to 
mTOR inhibitors can be accomplished safely and 
eﬀ ectively.
Early conversion
Protocols of early CNI withdrawal with conversion to 
mTOR inhibitors in the maintenance phase have been 
performed with three main aims. Th e ﬁ rst is to achieve 
optimal renal function at 1 year, because long-term graft 
and patient survival have been associated with 1-year 
renal function [11–13]. A 10 ml/minute decrease in GFR 
at 1  year is associated with a 2.1 odds ratio of kidney 
allograft loss 3 years after transplantation [14].
Th e second aim is to reduce the incidence of viral 
infection, because previous studies have shown a low 
incidence of cytomegalovirus (CMV) infection in SRL-
treated patients in comparison with CNI-treated 
patients [15]. A recent meta-analysis has shown that 
mTOR-inhibitor treatment, either alone or in 
combination with CNIs, signiﬁ cantly reduced the 
incidence of CMV infection after organ transplantation, 
suggesting that CMV prophylaxis may be dispensable 
with the use of mTOR inhibitors [16]. Furthermore, a 
signiﬁ cant increase in CMV-speciﬁ c CD8+ T-cell count 
has been observed in EVL-treated renal recipients 
compared with CsA-treated patients [17], and 
functional mTOR has recently been reported to be 
essential to CMV replication, suggesting a direct anti-
viral eﬀ ect of mTOR inhibitors [18]. A study has 
suggested that mTOR inhibitors also reduce the 
incidence of BK virus infection after trans plantation 
[19].
Th e third aim is to decrease the incidence of malig-
nancies. Th is aim is supported by several studies showing 
that mTOR-inhibitor-based regimens could reduce the 
incidence of neoplasia [20]. Moreover, it has recently 
been shown that conversion from a CNI to SRL in kidney 
transplant patients following a ﬁ rst skin cancer episode 
prevented the recurrence of skin cancer [21]. mTOR 
inhibitors have anti-neoplastic properties [22,23], in 
contrast to CNIs, which may induce cancer progression 
through mechanisms independent of host immunity [24].
Early conversion has been used in the CONCEPT study 
[25]. Two hundred and thirty-ﬁ ve nonimmunised patients 
transplanted with a deceased donor kidney received 
induction therapy with daclizumab and tri-therapy with 
CsA, MMF and steroids for 3 months. At 3 months, 192 
patients with proteinuria <1  g/day and GFR ≥40  ml/
minute were randomised to either continue CsA (n = 97) 
or to convert to SRL (n  =  95). MMF and steroids were 
planned to be discontinued at month 8.
Both groups were similar with respect to demographic 
and medical characteristics such as donor and recipient 
age, time of dialysis before transplantation, human leuko-
cyte antigen and CMV matching, incidence of delayed 
graft function and GFR. Th e primary endpoint, estimated 
renal function (creatinine clearance) at 1 year according 
to the Cockcroft–Gault equation, was signiﬁ  cantly better 
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in the SRL group (68.9 vs. 64.4  ml/minute, P  =  0.017). 
Similar results were observed when the GFR was 
calculated according to the Modiﬁ cation of Diet in Renal 
Disease formula (61.2 vs. 53.9  ml/minute, P  =  0.002) or 
was measured using iohexol (67.3 vs. 60.3  ml/minute, 
P = 0.004). Patient and graft survival were excellent, with 
no death and only one graft loss, which occurred in the 
CsA group. CsA and SRL dosages and levels were adapted 
at 12 months to a mean daily dosage of 226 mg CsA, with 
mean blood levels 2 hours after dosing of 749 ng/ml, and 
to a mean daily dosage of 3.2 mg SRL with a mean trough 
level of 9.6 ng/ml.
Th e incidence of BPAR episodes was not signiﬁ cantly 
higher in the SRL group (17% vs. 8%, P  =  0.07), while 
steroids were withdrawn in 72% and 78% of patients, 
respectively. Of note, most episodes of BPAR occurred 
just after withdrawal of steroids in the SRL group. Th e 
incidence of adverse events (stomatitis, acne, diarrhoea, 
high triglyceride levels) was slightly increased in the 
SRL group (60% vs. 44%, P = 0.025) and more patients 
discontinued SRL (16% vs. 7%). Interestingly, haemo-
globin, cholesterol, and proteinuria were similar in both 
groups. Th e number of patients with proteinuria >0.5 g/
day was also similar in both groups (12% in the SRL 
group vs. 9% in the CsA group). Some adverse events 
required adjustment of the MMF daily dose (1.7  g/day 
in the SRL group vs. 1.9  g/day in the CsA group, 
P <0.001). Aortic stiﬀ ness and biomarkers of endothelial 
activation were studied in 44 patients enrolled in the 
CONCEPT study [26]. One year after transplantation, 
the carotid-to-femoral pulse-wave velocity was 
signiﬁ cantly lower in the SRL group. In parallel, plasma 
levels of endothelin-1 decreased in the SRL group 
during the study, suggesting a beneﬁ cial eﬀ ect of SRL in 
preventing the development of cardiovascular 
complications after kidney trans plan tation. Conversion 
from CsA to SRL combined with MMF treatment 
3 months after transplantation was therefore associated 
with an improvement in renal function with a good risk-
to-beneﬁ t ratio.
Other studies have conﬁ rmed the CONCEPT study 
results, irrespective of the mTOR inhibitor used. At 
1 year, the renal beneﬁ t of early conversion from CNIs to 
mTOR inhibitors has been observed with both SRL 
[27,28] and EVL [29]. In the Spare-the-Nephron study, 
299 patients were randomised 1 to 6 months after trans-
plantation (mean 3.8 months) to continue CNI therapy or 
to convert to SRL (CsA, n = 31 or tacrolimus, n = 120) 
[28]. After 1  year, the mean percentage change from 
baseline of measured GFR was signiﬁ cantly higher in the 
MMF/SRL group compared with the MMF/CNI group 
(24.4% vs. 5.2%, P  =  0.012). Th e GFR, calculated 
according to Nankivell, was higher in the SRL group but 
the diﬀ erence was not signiﬁ cant (74.6 vs. 71.5  ml/
minute). In the SMART study, 161 patients with a low to 
moderate immunological risk were randomised 10 to 
24  days after transplantation to convert to SRL or to 
continue CsA [27]. Th e primary endpoint, renal function 
estimated at 1 year according to Nankivell, was signiﬁ -
cantly better in the SRL group (64.5 vs. 53.4 ml/minute, 
P = 0.0019). In the ZEUS trial, 300 patients were random-
ised at 4.5  months to continue CsA or be converted to 
EVL [29]. At 1 year, the EVL regimen was associated with 
a better renal function evaluated accord ing to Nankivell 
(71.8 vs. 61.9 ml/minute, P <0.0001). Similar results were 
reported in the HERAKLES study at the last meeting of 
the American Congress of Transplantation [30]. Th e 
percentage of BPAR at 1 year was low and similar in both 
groups in these studies (11.3% vs. 9.5% in Spare-the-
Nephron, 17% vs. 16% in SMART, 15% vs. 15% in ZEUS). 
Nevertheless, a signiﬁ cantly increased incidence of BPAR 
was reported in the EVL group in the randomised period 
in the ZEUS trial (10% vs. 6%, P = 0.04). One-year graft 
and patient survival were similar in both groups in all 
studies. However, more adverse events and more discon-
tinu ations were observed after conversion to mTOR 
inhibitors. Th ese studies (SMART, ZEUS, HERAKLES) 
assessing substitution of CsA with an mTOR inhibitor 
show that the renal beneﬁ t at 1 year (about 8 to 10 ml/
minute) was similar to those observed in CONCEPT, 
whereas it was reduced with tacrolimus [28,31].
Heilman and colleagues have reported a prospective, 
randomised, nonblinded trial of early tacrolimus elimina-
tion at 1 month (60 and 62 patients in the tacrolimus and 
SRL groups, respectively) [31]. In this study, the 
measured GFR was similar in both groups at 1 and 
2  years. Incidence of acute rejection was higher in the 
SRL group than in the tacrolimus group (Banﬀ  ≥IA: 13% 
vs. 5%, P = 0.15). Nevertheless, a very high percentage of 
withdrawal was observed in the SRL group (63% during 
the 2-year period). Other studies comparing the eﬃ  cacy 
and safety of mTOR inhibitors with tacrolimus do not 
support the advantages of mTORs [32–34]. Nevertheless, 
in all of these studies, mTOR inhibitors were used at 
trans plan tation (de novo) with a high percentage of early 
with drawal due to adverse events and sometimes 
subthera peutic dosing, especially in the Symphony study.
Early conversion to SRL with continuation of MMF 
may therefore represent an appropriate strategy for main-
tenance therapy in renal transplantation after careful 
screening at the time of transplantation. From these 
studies we can consider that the more suitable patients 
for early conversion are nonimmunised patients with 
good renal function (GFR >40  ml/minute), without 
previous severe acute rejection and subclinical rejection, 
in the absence of proteinuria >1  g/day and with donor-
speciﬁ c antibodies. Screening biopsy prior to conversion 
is important in selecting appropriate patients.
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Long-term clinical outcomes
Long-term clinical outcome studies are necessary to 
conﬁ rm the short-term beneﬁ ts of early CNI withdrawal. 
Patients who completed the initial 12  months of the 
SPIESSER and the CONCEPT studies were therefore 
enrolled in the post-SPIESSER and post-CONCEPT 
follow-up studies [35,36].
Th e 5-year results have been evaluated in 135 patients 
in the post-CONCEPT study (SRL, n  =  65 and CsA, 
n  =  70) and 130 patients in the post-SPIESSER study 
(SRL, n = 57 and CsA, n = 63). Patient survival and death-
censored graft survival were excellent in both studies and 
similar in both groups. In the SRL groups in the post-
SPIESSER and post-CONCEPT studies, patient survival 
was 93% and 97.4% and death-censored graft survival 
was 87% and 97.4%. However, the beneﬁ t on renal 
function in the SRL group, observed at 1  year, was 
maintained over 5 years in both studies (Figure 1). Renal 
function was signiﬁ cantly better in the SRL group in both 
studies in the intent-to-treat populations. Th e 5-year 
mean GFR, estimated according to the Modiﬁ cation of 
Diet in Renal Disease formula, was 59.1 versus 49.3 ml/
minute (P  =  0.0012) in the post-CONCEPT study and 
54.5 versus 45.3  ml/minute (P  <0.01) in the post-
SPIESSER study. Interestingly, this diﬀ erence was more 
pronounced in patients who remained in their random-
ised arm at year 5 (Figure 2), with a 14.9 ml/minute and a 
17.5  ml/minute diﬀ erence in the CONCEPT and 
SPIESSER studies, respectively. Moreover, a negative 
GFR slope with a progressive deterioration of renal 
function was observed in patients who received CsA in 
both studies, but was not seen in the SRL groups.
Mean daily SRL and CsA doses and trough levels of 
SRL were similar in the SPIESSER and CONCEPT 
studies (SRL doses, 2.7 and 2.4  mg/day; SRL levels, 8.7 
and 7.6 ng/ml; and CsA doses, 177 and 170 mg/day in the 
two studies respectively). In both studies, daily doses of 
MMF were adapted (CsA groups, 1,587 and 1,825  mg/
day; SRL groups, 1,403 and 1,542  mg/day in the two 
studies respectively). Interestingly, the percentage of 
steroid-free patients was higher in the SRL groups (76% 
and 73% vs. 69% and 61% in the two studies respectively). 
Th e occurrence of BPAR after 1  year was low in both 
studies (2 and 2 vs. 2 and 6 in the SRL and CsA groups 
from the SPIESSER and CONCEPT studies, respectively). 
Th e rate of patients with anti-human leukocyte antigen at 
5  years was also similar (22% and 12.3% vs. 16% and 
21.1% respectively). Th e 15% increased incidence of 
discontinuations observed at 1  year in the SRL groups 
was maintained at 5 years (40% and 44.6% vs. 24.2% and 
21.6% respectively), with an increased incidence of side 
eﬀ ects such as oedema, stomatitis, pneumonia and 
pyelonephritis. More patients with new-onset diabetes 
after transplantation were observed in the SRL group in 
the CONCEPT study but not in the SPIESSER study. Th e 
number of patients who developed malignancies (that is, 
skin cancers and nonskin malignancies) during follow-up 
was higher in the CsA groups in both studies in the ITT 
populations (9 and 9 vs. 4 and 6 respectively).
Lipid values (total cholesterol, low-density lipoprotein-
cholesterol, high-density lipoprotein-cholesterol and 
triglycerides) and the percentage of patients receiving 
lipid-lowering agents were similar at 5  years in the two 
treatment groups in both studies.
Figure 1. Intent-to-treat analysis of the estimated glomerular fi ltration rate. Analysis according to the Modifi cation of Diet in Renal Disease 
formula in the CONCEPT study (left) and in the SPIESSER study (right). *P <0.05, **P <0.01. GFR, glomerular fi ltration rate; M, month; SRL, sirolimus.
Gatault and Lebranchu Transplantation Research 2013, 2(Suppl 1):S3 
http://www.transplantation research.com/supplements/2/S1/S3
Page 4 of 7
Th ere were no diﬀ erences in haemoglobin values, 
either in the percentage of anaemic patients (deﬁ ned as 
haemoglobin value <11  g/dl) or in the percentage of 
patients receiving an erythropoietin-stimulating agent 
between groups in both studies. However, mean red 
blood cell counts were higher in the SRL group, whereas 
mean corpuscular volumes were lower. Interestingly, 
mean proteinuria was similar in both groups at 5 years in 
both studies (0.5 and 0.4 g/24 hours vs. 0.4 and 0.4 g/24 
hours). Moreover, the percentage of patients with pro-
tein uria >0.3  g/24 hours and the percentage of patients 
treated either with an angiotensin-converting-enzyme 
inhibitor and/or an angiotensin-receptor blocker were 
similar in both groups.
Th e 5-year results for CNI elimination with a SRL and 
MMF regimen therefore demonstrated that the renal 
beneﬁ t observed 1  year after transplantation was main-
tained and even increased with stability in the GFR in 
patients remaining on assigned SRL therapy – compared 
with patients remaining on assigned CsA therapy, in 
whom the GFR was progressively declining. Moreover, 
fewer malignancies were observed. Th ese beneﬁ ts were 
observed despite more SRL discontinuations due to early 
adverse events. Of note, similar long-term beneﬁ t was 
observed with the CNI-free regimen [36].
Conclusion
Early conversion to mTOR inhibitors in combination 
with MMF could be an appropriate strategy for main te-
nance therapy in renal transplant recipients with a low 
immunological risk, after careful screening at the time of 
conversion. Whether the beneﬁ ts observed in these trials 
could inﬂ uence long-term graft and patient survival 
remain to be determined.
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